Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development.
Nurudeen Oketade, Melissa D Chengalroyen, Dylan Kain, David M Lewinsohn, Karen M Dobos
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Nurudeen OketadeDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Melissa D ChengalroyenUCT Molecular Mycobacteriology Research, Institute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Dylan KainOregon Health and Science University, Portland, OR, United States.
David M LewinsohnOregon Health and Science University, Portland, OR, United States.
Karen M DobosDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Funding
Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State UniversityUC7AI180308 · NIAID · COLORADO STATE UNIVERSITY · PI Karen Marie Dobos · 2023 to 2026
$13.5M
T cell recognition of the MR1 presented microbial metabolomeR01AI147954 · NIAID · UNIVERSITY OF CHICAGO · PI ADAMS, ERIN JUNE, HILDEBRAND, WILLIAM · 2019 to 2023
$7.3M
Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)G20AI167348 · NIAID · COLORADO STATE UNIVERSITY · PI DOBOS, KAREN MARIE · 2021 to 2022
Flavin and deazaflavin biosynthesis are highly conserved pathways in mycobacteria, including in
Indexed as
FlavinsHistocompatibility Antigens Class IMycobacterium tuberculosisTuberculosisAnimalsDrug DiscoveryHumansMinor Histocompatibility AntigensMucosal-Associated Invariant T CellsVaccine Development5-deazaflavinFlavinsHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanflavin and deazaflavinflavin sequestrationMR1T and MAIT cellsmycobacteriatherapeuticstuberculosisvaccines
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development. · full record | OpenQuestion